ABSTRACT: During recent years, engineers and physicists have become increasingly interested in studying the electrical activity of the heart. Despite the fact that the heart is a complex and highly nonlinear system, its electrical behavior can be studied using a variety of experimental and clinical techniques, and can be modeled mathematically using relatively simple systems of diff erential equations, allowing scientists to perform both real and virtual (in silico) experiments to gain insights into its physiology and pathophysiology. Although these approaches have in recent years allowed great headway to be made into understanding the dynamic behavior of the heart, cardiac arrhythmias such as ventricular fi brillation still claim the lives of hundreds of thousands of people each year in the United States alone. Bridging the gap between understanding the mechanistic bases of arrhythmias and applying such knowledge to improving therapy presents one of the greatest challenges in the fi eld of cardiac electrophysiology. In this review, we describe the basic electrical properties and dynamic behavior of the heart and review the current state of the art in ventricular arrhythmia therapy. We also discuss some possibilities for future therapies, with the hope that such informed speculation will promote new investigations in these areas.
Effi cient pumping of blood throughout the body requires not only that there be suffi cient time for ventricular fi lling and ejection, but also that the heart musculature contracts in a coordinated manner. Given that the contraction of individual myocytes is driven by electrical excitation (through a process known as excitation-contraction coupling³), coordinated cardiac contraction requires that diff erent regions of the heart be electrically activated in a specifi c sequence. Th is sequential activation is facilitated by the anatomical arrangement of the heart into distinct but contiguous regions whose electrophysiological properties are markedly diff erent.⁴ Fıgure 1 illustrates the normal conduction system. During a normal sinus beat, the transmembrane voltage of cells in the sinoatrial (SA) node transiently increases, then decreases, over a time course of a few hundred milliseconds. A representative example of this voltage change (known as an action potential ) in a cell from the SA node is shown in Fıgure 2. Because the SA nodal region is electrically coupled to the right atrium, activation of the SA node causes a wave of activation to spread throughout the atria. A representative action potential recorded from a myocyte in the right atrium is also shown in Fıgure 2. Electrical activation of the atria is soon followed by mechanical contraction of the atria.
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Electrical excitation of the atria leads to activation of the atrioventricular (AV) node, the anatomical location of which is indicated in Fıgure 1. In anatomically normal hearts, the AV node provides the only electrical connection between the atria and ventricles. Th e transient increase in transmembrane voltage at the AV node, illustrated by the representative action potential in Fıgure 2, leads to the subsequent excitation of the bundle of His, the left and right bundle branches, and the Purkinje fi bers. Branches of the His-Purkinje system radiate throughout the ventricular tissue, and thus excitation of the His-Purkinje system leads to the excitation and subsequent contraction of the ventricles. Th e electrophysiological properties and anatomical layout of the AV node and His-Purkinje conduction system ensure that suffi cient time exists for blood to fl ow from the atria to the ventricles before the ventricles contract. Ventricular contraction forcefully propels oxygenated blood from the left ventricle into the aorta and the systemic circulation and deoxygen- transmural direction). Th is spatial distribution of repolarization characteristics within the ventricular wall is referred to as the transmural dispersion of repolarization.⁵ Th e markedly diff erent electrophysiological properties between and within each region of the heart, manifested as the widely varying action potential morphologies illustrated in Fıgure 2, are predominantly caused by diff ering levels of membrane ion channel expression between and within each region.⁴ For example, the action potentials of cells in the nodal regions of the heart are characterized by a slow upstroke velocity, mediated predominantly by L-type calcium channel currents (I Ca,L ), whereas in other regions the rapid upstroke velocity initiating the action potential is mediated by a fast sodium channel current (I Na ). Th e slow spontaneous depolarization seen in the nodal cells during diastole is mediated by a number of currents, including the pacemaker current (or "funny" current, I f ) and the T-type calcium channel current (I Ca,T ) and a lack of inward rectifying potassium current (I K1 ), whereas the lack of spontaneous depolarization in other regions of the heart indicates that the channels conducting these currents either are not expressed or play a diff erent functional role in these regions. Fıgure 2 also illustrates how, among those regions containing action potentials that exhibit rapid upstrokes, the action potentials have markedly diff erent durations. Because repolarization of the action potential and, therefore, its duration is controlled predominantly by the balance of repolarizing (outward) and depolarizing (inward) currents, and because the predominant repolarizing currents in these regions are potassium currents, it is not surprising that the levels of expression of the potassium channels active during repolarization diff er greatly in each region.⁶ Although it was mentioned above that the danger of an arrhythmia is not related to any eff ects that the abnormal rhythm has on the heart tissue itself, it should be noted that a persistent or permanent arrhythmia, especially in the atria, can lead to electrical remodeling.⁷ Electrical remodeling gradually changes the electrophysiological properties of the tissue, primarily through such molecular processes as altered ion channel expression or modifi ed channel gating properties, and can subsequently infl uence the likelihood of recurrence and the persistence of the arrhythmia.
Restitution
Despite the widely varying levels of expression of the ion channels controlling repolarization in diff erent regions of the heart, the repolarization characteristics of cells in each region can be characterized in a fairly straightforward manner. Th e most widely used technique for quantifying the repolarization characteristics of a cell or tissue is the restitution curve.⁸-¹⁰ Th is curve, an example of which is shown in Fıgure 4, is a plot of the duration of the action potential (APD) against the preceding therapies for cardiac arrhythmias rest period (the diastolic interval, or DI). Such a curve reduces the extremely highdimensional dynamics of the cardiac cell to a simple one-dimensional relationship, expressed mathematically as the discrete map equation APD n+ ₁ = f (DI n ). 152 Points A, B, and C on the curve correspond to the second of the two action potentials in each pair of action potentials beneath the curve.
The fi rst action potential is identical in each pair, refl ecting the identical action potential histories preceding the fi rst action potentials shown. To generate the APD restitution curve, the diastolic interval (DI) following the penultimate action potential is varied, and the duration of the resulting action potential is plotted as a function of the preceding DI. As the pairs of action potentials demonstrate, APD shortens as DI is shortened, leading to a restitution curve with the general shape as shown. APD can be measured in a number of ways, but two methods are often used. In the fi rst method, a transmembrane voltage measurement threshold (say, -50 mV) is selected, and the time between consecutive crossings of this threshold is measured. If the intervening time is characterized by a transmembrane voltage more negative than threshold, the measured length of time corresponds to the DI; if the voltage is more positive than threshold, the measured length of time corresponds to the APD. In the second method, APD is measured between the point of maximum upstroke velocity (i.e., maximum dV/dt) and a particular voltage during repolarization, calculated as
Th e general shape of the APD restitution curve shown in Fıgure 4 is representative of the restitution behavior of cells from all regions of the heart. Although the exact shape of the curve within the (DI, APD) space is dependent upon the particular experimental protocol used to obtain the data,¹¹-¹³ the trend of decreasing APD for decreasing DI is invariant across the heart. Because the action potential is produced by current fl ow through large populations of individual ion channels, one might expect that, regardless of the duration of the DI, the amount of ionic current passing through the membrane would be the same during every action potential, and, hence, the action potential shape and duration would be the same for every DI. Th is would correspond to a restitution curve that is a horizontal line. Th e reason that this is not the case is that the amount of current carried by a population of ion channels in a cell over a given period of time is highly dependent upon how much time the channels have had to recover since they were last stimulated. If a cell is allowed less time to recover between consecutive stimuli, some of the channels in the population may, for example, be caught in a nonconducting state; thus, both the proportion of such channels conducting current following a brief recovery time and the total ionic current fl ow through a population of such channels will be smaller than if the population was allowed more time to recover between stimuli. As Fıgure 4 indicates, the overall trend resulting from the combined activity of all populations of ion channels in a typical atrial or ventricular myocyte is that as the DI is reduced, the repolarizing currents active during the plateau phase of the action potential tend to dominate the depolarizing currents, resulting in a shortening of the action potential. Most cardiac myocytes cannot elicit action potentials at all (i.e., they become refractory) as the DI becomes small, leading to the termination of the restitution curve at a small but non-zero value of the DI.
Th e continuous nature of the restitution curve in Fıgure 4 seems to suggest that if a cardiac cell is stimulated at a constant rate, and then the rate at which the cell is stimulated is gradually increased, the APD and DI will decrease continuously. Th is trend (continuous shortening of the action potential) will supposedly continue for faster and faster stimulation rates until such time as the end of the restitution curve is reached, and no further action potentials will be elicited due to the refractoriness of the cell. In other words, the restitution curve might appear to indicate that, until the refractory period is reached, a 1:1 response (one APD output per stimulus input) will occur. However, in some cardiac cells, a critical stimulation rate exists at which a bifurcation to a qualitatively diff erent behavior occurs.⁸,¹⁴ Above this critical rate, a stable period-2 behavior occurs (instead of the previous period-1 behavior), during which the action potential duration alternates on a beat-to-beat basis and returns to a given state after every two periods (i.e., after two action potentials) instead of after one, as shown in Fıgure 5. Th at is, during alternans, there is a 2:2 (instead of a 1:1) therapies for cardiac arrhythmias response-two action potentials of diff erent duration occur for every two periodic stimuli given. Th e particular excitation rate at which the action potential activity in a given cell bifurcates to alternans (i.e., makes the transition from a 1:1 to 2:2 response) is dependent upon the membrane currents and intracellular regulatory mechanisms operating in that cell. Th e implications of APD alternans for ventricular arrhythmias will be discussed later.
Wave Propagation
Th e spread of electrical excitation from one electrophysiologically distinct region of the heart to another, and between cells within each region, is mediated by the fl ow of ions between adjacent cells through bridging proteins known as gap junc- . Action potential duration bifurcation diagram, generated with the CVM model of the action potential. 153 While pacing cardiac myocytes at a relatively slow rate, identical action potentials occur each time a stimulus is applied (i.e., 1:1 behavior). However, in many types of myocytes, increasing the pacing rate causes the action potential behavior to bifurcate, such that for every two stimuli, two different action potentials occur (i.e., 2:2 behavior).
In this fi gure, L represents the long action potential (corresponding to the upper arm of the bifurcation diagram), and S represents the short action potential during alternans.
tions. Th ese proteins, which possess mild time-dependent gating properties¹⁵-¹⁷ but which can eff ectively be thought of as passive ohmic resistors, provide low-resistance pathways for the spread of excitation throughout the heart. When one cell has a diff erent transmembrane voltage from its neighbor, the voltage diff erence drives current (predominantly carried by cations) through each gap junction (as shown in Fıg. 6) according to Ohm's law. Th is current decreases the voltage diff erence between the cells by lowering the higher voltage (the cation "source") and raising the lower voltage (the cation "sink"). In this manner, if a cell or small group of cells in a quiescent excitable tissue is externally stimulated so that the cell or group of cells generates action potentials, intercellular current fl ow will bring the previously quiescent cells immediately adjacent to the excited region to their action potential fi ring threshold, causing these cells to generate action potentials and thus to serve as an excitatory current source for their neighboring cells in the tissue. Provided that there is no source/sink mismatch,¹⁸ such intercellular current fl ow results in propagation of the action potential through the tissue. Th e rate at which an activation wave will propagate through a tissue is dependent upon how quickly a given cell can bring its neighboring cells to their action potential fi ring threshold. Given that ionic current must pass between cells to facilitate the generation of action potentials, and given that gap junctions connecting adjacent cells can be thought of as ohmic resistors, the rate at which ions fl ow between cells in a tissue will depend upon both the voltage diff erence between each pair of cells, and the size of the resistance provided by the gap junctions. Consider two identical cells connected by a passive resistor, where one cell acts as a source while the other cell acts as a sink. Th e rate at which the sink cell is brought to its action potential fi ring threshold will be dictated by the rate at which the source cell voltage increases. Th at is, if the upstroke velocity of the action potential in the source cell is very fast, the rate at which the sink cell voltage changes will also be fast, meaning that the sink cell will be brought to its fi ring threshold more quickly than if the upstroke velocity of the source cell had been slower. Th erefore, if two diff erent pieces of tissue having identical gap junction connectivity patterns and resistances are compared, where one tissue comprises cells that possess rapid upstroke velocities while the cells in the other tissue possess slow upstroke velocities, an activation wave will propagate more quickly through the tissue containing the cells with rapid upstroke velocities.
Within atrial and ventricular tissue, the upstroke velocity of the action potential in a given cell is predominantly dependent upon the fast sodium channel current (I Na ), as was mentioned previously. As a result of ion channel recovery processes similar to those underlying APD restitution, the amount of I Na available in each cell, and therefore the upstroke velocity, is highly dependent upon the amount of time between consecutive stimulations of each cell. As the DI becomes smaller, not only does the APD become shorter (Fıg. 4), but also the amount of available I Na reduces (because the population of fast sodium channels in the tissue is given insuffi cient time to fully recover, and thus some sodium channels are caught in a nonconducting state). Th is decreases the upstroke velocity of the action potential and therefore results in a reduction of the rate at which the activation wave propagates through the tissue. Th is trend of slowing conduction velocity as DI shortens is known as conduction velocity (CV) restitution.¹⁹-²¹ Like the APD restitution curve, this behavior is quantifi ed using a CV restitution curve, examples of which are shown in Fıgure 7.
I.C. Classifi cation of Arrhythmias
As discussed above, the effi cient mechanical operation of the heart relies on the coordinated generation and propagation of waves of activation that initiate contraction. Abnormalities in the mechanical pumping ability of the heart can therefore be caused by abnormalities in the generation of the activation wave (i.e., the propagating action potential), the propagation of the activation wave, or both. Th e mechanisms initiating and sustaining an arrhythmia may thus be classifi ed according to whether they are related to abnormalities in the generation of the activation wave or the propagation of the activation wave (i.e., reentry), as shown in Fıgure 8.²²
Abnormal Impulse Generation
Abnormal action potential (i.e., impulse) generation may be related either to triggered activity or to automaticity. Triggered activity is activity that arises from regular or irregular transmembrane voltage oscillations that occur during or immediately after an action potential. Depending on when such afterdepolarizations occur, they may be classifi ed as either early (if they occur during repolarization of the preceding action potential) or delayed (if they occur during the diastolic interval).²³ Both kinds of afterdepolarizations are shown in Fıgure 9. Th e problems associated with afterdepolarizations arise from the fact that they may trigger extra action potentials therapies for cardiac arrhythmias where otherwise there would have been no response. Such triggered activity may be suffi cient to initiate an arrhythmia.²³ Automaticity in cardiac electrophysiology is defi ned as the ability of cardiac cells to generate spontaneous action potentials. Automaticity occurs because of the presence of ionic currents that spontaneously drive the transmembrane voltage toward less negative values following the preceding action potential. If the transmembrane voltage reaches the action potential fi ring threshold, an action potential ensues. As Fıgure 2 shows, both the SA and AV nodes exhibit intrinsic automaticity (indicated by the slow depolarization of these cells between consecutive action potentials). Th e SA node normally displays the highest intrinsic rate (60-100 beats per minute²³). Th e AV node, which has an intrinsic fi ring rate of around 40-60 beats per minute,²³ is referred to as a subsidiary pacemaker, because it takes over the function of initiating excitation of the heart only when SA nodal function is compromised or when impulses originating from the SA node fail to propagate to the AV node and ventricles.
(Although not shown in Fıg. 2, the Purkinje fi bers are also subsidiary pacemakers, exhibiting low-frequency automaticity at 20-40 beats per minute.²³) According to the classifi cation scheme in Fıgure 8, two kinds of problems associated with automaticity may occur. If the rate at which a pacemaker generates action potentials increases (i.e., enhanced automaticity), such extra activations may be suffi cient to trigger an arrhythmia. Alternatively, one of the subsidiary pacemakers in the heart may generate an unexpected spontaneous beat (parasystole), even though it may not exhibit enhanced automaticity. During normal activation of the heart, the subsidiary pacemaker rhythms are reset by the propagating activation wave initiated by the dominant SA node pacemaker. If one of the subsidiary pacemakers is somehow protected from the incoming impulse by being surrounded by poorly or nonconducting tissue such that its rhythm is not reset, but is not so isolated that spontaneous activations cannot activate the rest of the myocardium, the unexpected ectopic activity from the parasystolic focus may be suffi cient to trigger an arrhythmia.²⁴
Reentry
As their name implies, reentrant arrhythmias occur when previously activated tissue is activated repeatedly because the activation wave, which did not extinguish naturally, reenters the same anatomical region and reactivates it. Th is rapid reactivation process repeats indefi nitely until the excitability of the tissue in the reentrant circuit is somehow aff ected. In many situations the excitability of the reentrant circuit tissue is naturally interrupted through the interaction of the reentrant activation wave with an activation wave originating from some other region of the heart.
Reentrant arrhythmias may be one of three types: circus movement, refl ection, and phase 2. Refl ection reentry and phase 2 reentry typically occur in very small, highly localized areas of tissue such that they appear as series of focal activations. Because of this, they are usually referred to as types of microreentry. Circus movement reentry, on the other hand, usually does not have a focal appearance and therefore is referred to as macroreentry.
Refl ection reentry has been demonstrated in Purkinje fi bers containing a central unexcitable region.²⁵ In such situations, anterograde conduction of the action poten-tial (toward the unexcitable region) is sometimes followed by a retrograde wavefront (away from the unexcitable region) that seems to be refl ected by the unexcitable region, causing a "return extrasystole." Th is phenomenon is clearly seen in Fıgure 10, in which a refl ected action potential appears at the proximal end of the fi ber after the third activation wave has passed to the distal end. Phase 2 reentry occurs when the dome of an epicardial action potential propagates from sites at which it is maintained to sites where it is lost, as shown in Fıgure 11. In such a situation, local reactivation of the epicardium may occur, generating closely coupled extrasystoles.²⁶ Th e third type of reentry, and by far the most common, is known as circus movement reentry. Th is type of reentry refers to the circulation of an activation wavefront around an anatomical or functional obstacle in the heart, leading to repetitive activation of the tissue at a frequency that is dependent upon the velocity at which the wavefront conducts around the obstacle and the length of the path around the obstacle.²⁷ Th e simplest model of circus movement reentry is the closed ring, shown in Fıgure 12, in which the activation wavefront rotates around an anatomical obstacle. Circus movement reentry can be identifi ed by the following characteristics: (1) an area of unidirectional conduction block must exist, causing the activation wavefront to move in one direction only around the ring; (2) the activation wavefront must After the third action potential has propagated along the fi ber, a return extrasystole appears at the proximal end of the fi ber, giving the appearance that the action potential has been "refl ected" by the unexcitable region. This phenomenon is known as refl ection reentry.
(Reproduced from Antzelevitch C. Clinical application of new concepts of parasystole, refl ection, and tachycardia. Cardiol Clin. 1983;1:39-50, with permission from Elsevier.) therapies for cardiac arrhythmias move around an anatomically distinct pathway, returning to its point of origin and then following the same path again; and (3) interruption of the reentrant circuit at any point along its path should terminate the circus movement. For a given closed therapies for cardiac arrhythmias circuit to form a reentrant ring, the rotation time around the ring must be longer than the recovery period of all segments of the circuit. In the absence of an anatomical obstacle, it is still possible for circus movement reentry to occur. In such a situation, the activation wavefront rotates around a region that may be anatomically continuous but which is functionally discontinuous.²⁸,²⁹ Such a situation occurs in the leading-circle/fi gure-of-eight/spiral-wave models of reentrant arrhythmias,²² in which a functional discontinuity (instead of an anatomical discontinuity) serves as a pivot point about which the activation wave rotates. Th e functional discontinuity can be created by a region of depressed excitability (from residual or sustained refractoriness) or, in the case of spiral waves, by the high degree of curvature of the activation wave front at the pivot point.³⁰ Fıgure 13 illustrates a clockwise-rotating spiral wave recorded experimentally from canine epicardial tissue.³¹
I.D. Ventricular Arrhythmias
Ventricular arrhythmias may be defi ned as single or repetitive activations of the ventricles that originate distal to the bifurcation of the bundle of His (Fıg. 1) and do not require atrial or proximal AV nodal tissue for their maintenance.³² Broadly speaking, ventricular arrhythmias may be categorized either as premature ventricu- lar contractions (PVCs) or as ventricular tachyarrhythmias, the latter including ventricular tachycardia (VT) and ventricular fi brillation (VF). By this classifi cation scheme, PVCs are single or paired ectopic beats that originate in the ventricles, whereas ventricular tachyarrhythmias are repetitive forms of three or more consecutive ventricular ectopic beats.³² Th e activation patterns underlying ventricular tachyarrhythmias exhibit a variety of levels of organization, with fi brillation being the most disorganized. Th e disorganized activation associated with ventricular fibrillation leads to uncoordinated contraction and a drastic reduction in blood fl ow around the body (i.e., hemodynamic failure). Unless defi brillation (either external or internal) restores normal ventricular activation patterns within a few minutes of the onset of the arrhythmia, ventricular fi brillation invariably leads to death.
Regardless of the duration of the ventricular arrhythmia, the mechanisms underlying the initiation and maintenance of the arrhythmia remain the same as those listed in Fıgure 8.
Focal Activation in the Ventricles
Rapid focal activation caused by early or delayed afterdepolarizations (i.e., triggered activity), normal or abnormal automaticity, or microreentry (i.e., refl ection and phase 2 reentry) may initiate, or be the underlying mechanism of, a number of ventricular tachyarrhythmias. In such pathological states, rapid focal activations in the ventricles may occur, generating premature activations that can take over the dominant pacemaker role from the SA node, leading to a tachyarrhythmia.
An example of such a pathological state is Long-QT (LQT) syndrome, in which rapid focal activation may be important in initiating Torsades de Pointes (TdP), a ventricular tachyarrhythmia.³³ In LQT syndrome, the gating characteristics of ionic currents are aff ected, causing the action potential to lengthen and, as a result, the Q-T interval of the electrocardiogram to lengthen.³⁴ Th is action potential lengthening may be accompanied by an increase in the transmural dispersion of repolarization in the ventricles and the generation of early afterdepolarizations (Fıg. 9) in cells in the ventricles, which may be suffi cient to trigger TdP.³⁵ After initiation, TdP is generally thought to rely on circus movement reentry for its maintenance.³⁶
Macroreentry in the Ventricles
Although rapid focal activations are often suffi cient to initiate and sometimes to maintain a ventricular tachyarrhythmia, the mechanism underlying the maintenance of most ventricular tachyarrhythmias is circus movement reentry (i.e., macroreen-therapies for cardiac arrhythmias try). As mentioned previously, circus movement reentry can be either anatomical or functional, but in either case, one of the conditions essential for the initiation and maintenance of circus movement reentry is the development of unidirectional block, which occurs when a wavefront fails to propagate in one particular direction but can continue to propagate in other directions; in the case of the closed ring in Fıgure 12, unidirectional block results in propagation around the ring in one direction only. Th e conditions for developing unidirectional block in two-and three-dimensional tissue are provided by the dynamic interaction of activation wavefronts and tissue refractoriness (both of which are heavily infl uenced by APD and CV restitution) as well as the anatomical structure of the tissue.
Spatial dispersion of repolarization and refractoriness are important considerations in the development of unidirectional block. As mentioned previously, the transmural wall of the ventricle contains cells with markedly diff erent repolarization characteristics, contributing to an intrinsic heterogeneity in the dynamics of ventricular refractoriness. In addition, intrinsic heterogeneity of repolarization may also be present in the apical-basal direction.³⁷,³⁸ If an ill-timed and ill-positioned focal activation spontaneously occurs when diff erent parts of the ventricle are undergoing diff erent phases of repolarization, the spontaneous activation wavefront will propagate successfully into the region in which the cells are no longer refractory, but will not propagate in the direction in which cells remain refractory as a result of their longer intrinsic action potential, resulting in unidirectional block. Provided that other requisite conditions are satisfi ed, this may provide the substrate for the development of circus movement reentrant tachyarrhythmias.³⁹ It is perhaps surprising that refractoriness can also become spatially dispersed in electrophysiologically homogeneous tissue (i.e., tissue that lacks any intrinsic heterogeneity in repolarization). As a consequence, circus movement reentry can occur in electrophysiologically homogeneous tissue. For this to occur, conditions must exist in which the intrinsic heterogeneity of repolarization, described above, is functionally induced in tissue that is intrinsically homogeneous. Th at is, during a particular activation of the tissue, parts of the tissue must be induced to exhibit signifi cantly longer action potentials than other, adjacent parts of the tissue. Th is functional heterogeneity in APD can occur if, for example, the individual cells in the tissue have a propensity toward developing APD alternans. If, on a beat-to-beat basis, the entire tissue exhibits a long action potential followed by a short action potential, the alternans is termed concordant. However, in some situations it may be possible to generate discordant alternans, wherein one (or more) region(s) of the heart exhibit a short action potential while other region(s) exhibit a long action potential during the same beat. Th is spatial distribution of long and short action potentials reverses each beat, as each cell alternates in duration but diff erent regions of the ventricles alternate out of phase with each other.⁴⁰,⁴¹ In a manner similar to the intrinsic spatial dispersion of refractoriness provided by the transmural and apical-basal electrophysiological properties of the ventricles, such discordant alternans can create a functional spatial dispersion of refractoriness that, in the presence of premature focal activations, may lead to the development of unidirectional conduction block.⁴² Discordant alternans may therefore provide a suitable substrate for the initiation of circus movement reentrant tachyarrhythmias in the ventricles.⁴³
I.E. The Electrophysiology Study
Th e discussion thus far has focused on the principles underlying the initiation and maintenance of arrhythmias in general and ventricular tachyarrhythmias in particular. It is worthwhile at this point to discuss briefl y the way in which arrhythmias are studied clinically with an electrophysiology study, which is where many of the dynamic features of cardiac tissue described thus far can be assessed.
Conceptually, the electrophysiology study is quite straightforward. By recording and pacing from localized areas in the heart using electrode catheters inserted through the venous circulation, the electrophysiology study can help to assess the function of the SA and AV nodes and the His-Purkinje system, to determine the characteristics of reentrant arrhythmias, to map the location of arrhythmogenic foci for ablation (generation of scar tissue to disrupt arrhythmogenic substrates), and to assess the effi cacy of antiarrhythmic drugs and devices such as implantable cardioverter defi brillators.⁴⁴ All of these assessments are possible because pacing introduces artifi cial premature electrical impulses at precisely timed intervals, allowing the clinical electrophysiologist to take control of the heart and probe its functioning in detail.
Th e utility of the electrophysiology study in assessing vulnerability to ventricular tachyarrhythmias is perhaps most clearly seen in the study of macroreentry. As was mentioned previously, the majority of ventricular tachyarrhythmias rely on circus movement reentry for their maintenance. Th e power of the electrophysiology study lies in its ability to use pacing to controllably induce and terminate reentry. Given that macroreentry usually relies on the presence of an anatomically defi ned circuit, external pacing at just the right frequency can often be used to artifi cially induce reentry in patients whose hearts contain such reentrant circuits. If external pacing during the electrophysiology study can induce sustained reentry, a similar sequence of naturally occurring beats could, in theory, induce the same reentrant arrhythmia outside of the clinic. Th erefore, the ability to induce reentry during an electrophysiology study provides an indication of vulnerability to reentrant tachyarrhythmias. As a result, the electrophysiology study can be helpful (although not perfect⁴⁵) in deciding which patients should be treated using surgical or implantable device therapies.
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II. CURRENT TREATMENT OF ARRHYTHMIAS II.A. Pharmacological Treatment of Arrhythmias-A Brief History
Th at drugs can infl uence cardiac arrhythmias has been recognized for at least 40 years. However, little was known about the mechanisms underlying arrhythmias (i.e., abnormal impulse generation and propagation) when the fi rst attempts were made to treat arrhythmias using pharmacological agents. As a result, early drug therapies for treating arrhythmias were based on empirical evidence, targeting diseases or symptoms whose underlying mechanisms were poorly understood. Very few drugs were initially available, and the ones that were available were not completely eff ective and often caused serious adverse eff ects. Drug effi cacy was judged anecdotally from clinical experience, and few large controlled clinical trials had been performed.⁴⁶
In the late 1960s and early 1970s, as more drugs for treating arrhythmias became available, the Vaughan-Williams scheme for classifying drugs according to their major mechanism of action (i.e., according to which channel they bind and block) became popular.⁴⁷ Such a classifi cation scheme facilitated thinking about the antiarrhythmic activity of these drugs from an electrophysiological perspective.
Th e Vaughan-Williams classifi cation scheme is illustrated in Table 1 . As indicated, each class of drugs targets a specifi c group of ion channels in the cell membrane, and as a result each drug aff ects the action potential in diff erent ways. Class I drugs, for example, block the fast sodium channels responsible for the rapid upstroke of the action potential seen in atrial, ventricular, and Purkinje fi ber tissue (Fıg. 2). Because of this, the upstroke of the action potential is slowed, slowing conduction velocity. Class III drugs, on the other hand, block potassium channels. Given that potassium channels play a major role in controlling action potential repolarization, blockade of potassium channels by class III drugs causes a lengthening of the action potential, with the expectation that such lengthening would make reentry less likely (by extending tissue refractoriness). Some drugs, however, aff ect more than one class of ion channels and therefore become very diffi cult to classify using the Vaughan-Williams scheme.
Although antiarrhythmic drugs continued to be developed throughout the 1970s and early 1980s, the publishing of results from the Cardiac Arrhythmia Suppression Trial (CAST) in 1989 forced a major rethinking of the use of drugs in the treatment of arrhythmias.⁴⁸ Th e CAST, a multicenter, randomized, placebo-controlled study, was designed to test the hypothesis that because ventricular ectopic beats following a myocardial infarction (the formation of a region of dead tissue in the ventricles, usually due to a transient or permanent loss of oxygen to that region of the heart) were a risk factor for sudden death, suppression of ventricular ectopy would reduce the incidence of cardiac death. Following a pilot study⁴⁹ in which three Class IC antiarrhythmic drugs were shown to suppress spontaneous ventricular depolarizations in a target population, the CAST recruited 2309 patients to see whether arrhythmia suppression using these drugs would prolong survival.
Despite the promising results from the pilot study, the CAST revealed that two of the three class IC drugs, encainide and fl ecainide, paradoxically induced sustained arrhythmias in patients who, at baseline, did not exhibit sustained arrhythmias. In patients treated with either encainide or fl ecainide, survival rates actually decreased compared to patients treated with a placebo.⁴⁸ A likely mechanism underlying the proarrhythmic eff ect of fast sodium channel block induced by class IC drugs is the slowing of activation wave propagation, which can actually promote the development of circus movement reentry.⁵⁰ Such proarrhythmic eff ects were in marked contrast to the belief in the antiarrhythmic potential of such drugs before the CAST study. Although the proarrhythmic eff ects of certain drugs had been reported prior to the 
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CAST study, the notion that putative antiarrhythmic drugs might kill more people than they save made safety a key consideration in the development of new drugs, cardiac and otherwise. Th e CAST results also led to the proposal that identifying and targeting specifi c arrhythmia mechanisms when developing antiarrhythmic drugs should supplant the nonspecifi c or poorly understood drug actions used to date.⁴⁶
II.B. Current Pharmacological Treatment of Arrhythmias
A recent book on the pharmacological treatment of cardiac arrhythmias states that the fi rst principle of treating arrhythmias pharmacologically is to "avoid using antiarrhythmic drugs whenever possible."⁵¹ In view of the fact that the results of a number of large, multicenter, randomized, placebo-controlled studies investigating the infl uence of an array of putative antiarrhythmic drugs have been disappointing, there has been an ongoing shift in emphasis from pharmacological to nonpharmacological approaches in the therapies for ventricular arrhythmias.⁵² Implantable devices (such as implantable cardioverter defi brillators) and ablative therapies have now become the therapies of choice for many patients, refl ecting the demonstrated effi cacy of these approaches and the recognition of the inherent risks, particularly the proarrhythmic eff ects, associated with long-term antiarrhythmic drug use.⁴⁶ Despite their limitations, antiarrhythmic drugs are still used as adjunctive therapies to nonpharmacological treatments; one such example is to prevent ventricular arrhythmias in certain patients who have implantable cardioverter defi brillators in order to minimize the need for device intervention.⁴⁶ β-blocker drugs are also useful, particular in reducing mortality in patients with certain kinds of heart disease. In such patients, increased β-adrenergic stimulation (and a corresponding increase in heart rate) may be associated with sudden death, and thus β-blockade may be antiarrhythmic through its slowing of heart rate.⁵³
II.C. Implantable Cardioverter Defi brillators
Although pharmacological treatment is most useful for preventing tachyarrhythmias from occurring in the fi rst place, implantable cardioverter defi brillators (ICDs) attempt to terminate tachyarrhythmias once they have initiated. In the 1970s, Mirowski and Mower⁵⁴ led the development of the fi rst implantable defi brillator. Th is device was capable of automatically monitoring and analyzing the heart rhythm and delivering a powerful defi brillation shock upon detection of ventricular fi brillation. Following the fi rst implantation of such a device in 1980,⁵⁵ ICDs have undergone signifi cant technological advancements and have made the transition from a mar-ginal therapy to the therapy of choice for ventricular tachyarrhythmias.⁵⁶ In 2003, an estimated 150,000 defi brillators were implanted in patients in the United States, with that number expected to increase in the coming years.⁵⁷ Th e primary component of an ICD system is the pulse generator, which is a sealed metal (normally titanium) box (Fıg. 14). Original generators were large⁵⁸ (160-190 cm³), necessitating abdominal implantation, but they are now small (as small as 30 cm³) and unobtrusive, enabling subcutaneous implantation in the anterior therapies for cardiac arrhythmias chest wall. Th e pulse generator contains a battery (typically lithium/silver vanadium oxide), capacitors for storing shock charge, a microprocessor, a telemetry module (for communicating with an external diagnostic instrument at the time of implantation and during subsequent clinic visits), and additional electrical components. Electrical leads connect the pulse generator to the heart. Originally, ICD leads were attached to the heart via epicardial patches, necessitating debilitating open-chest surgery. In 1988, the fi rst transvenous lead was used, an advance that greatly increased the rate of adoption of ICD technology by eliminating the need for open-chest surgery. In current ICD systems, one or more leads are connected to the pulse generator via an epoxy resin header and threaded via the subclavian vein into the heart, where they contact the endocardial surface of the chamber of interest. Th e ICD lead contains bipolar measuring/stimulating (sensing/pacing) electrodes as well as high-energy defi brillation coils. Th e telemetry module allows the ICD to be "interrogated" noninvasively to determine if it is functioning properly and also to reprogram the device if it is determined that its therapeutic algorithms need to be adjusted. Th e fi rst task of the ICD is to detect tachyarrhythmias. Th is is accomplished by the microprocessor, which continuously analyzes signals acquired via the endocardial leads. Th ese signals are fi ltered to remove unwanted components so that ventricular activation events can be identifi ed accurately. Following such identifi cation, algorithms process the information to determine whether an arrhythmia is occurring. Because mistakes can be deadly (in the case of a missed arrhythmia) or painful (in the case of nonpathological rhythm identifi ed as a ventricular arrhythmia such that a defi brillation shock is delivered to a conscious patient), devices typically employ a combination of complementary detection techniques that examine such variables as rate, morphology, onset, regularity, and relationship of atrial and ventricular activity. Extensive research into such electrocardiogram processing techniques has greatly improved the accuracy of detection algorithms.
Once a tachyarrhythmia is detected, a suitable therapy must be delivered. Th e fi rst therapeutic modality is antitachycardia pacing (ATP), which applies one or more series of suprathreshold (but not perceptible to the patient) stimuli (Fıg. 15). ATP is typically attempted for ventricular tachyarrhythmias exhibiting rates of up to 200-220 beats/minute.⁵⁹ A variety of ATP algorithms exist, including burst pacing, wherein bursts of stimuli are delivered at a programmable rate faster than the detected VT rate; and ramp pacing, in which each stimulus interval is decrementally shorter than the preceding interval. Both approaches aim to force a stimulated wave into the reentrant circuit to extinguish the reentrant wave. It was recently reported that ATP was eff ective in terminating 90% of ventricular tachyarrhythmias on which it was attempted.⁶⁰ Occasionally, ATP can have the deleterious eff ect of accelerating the tachyarrhythmia, which puts the patient at increased risk of hemodynamic failure. In such cases, rescue high-energy defi brillation shocks are delivered instead.
Defi brillation shocks are delivered when ATP fails or as primary therapy when arrhythmias such as ventricular fi brillation are detected (Fıg. 15). Upon the detection of such an event, the capacitors within the pulse generator are charged rapidly by the battery. Th e capacitive charge is then discharged via the high-energy electrode coils that are part of the ICD lead system, achieving a defi brillation voltage of 700 or At the beginning of the record, ventricular tachycardia is apparent because of the "dissociation" of the more rapid ventricular activity from the atrial activity (sinus rhythm). Following detection and classifi cation of this arrhythmia, the device delivered eight ATP stimuli (the large, clipped pulses in the ventricular electrocardiogram), which successfully terminated the tachycardia. Following the ATP therapy, the device performed "post-shock" dual-chamber pacing, as evidenced by the pacing stimuli artifacts seen in both electro cardiograms.
In Panel B, which is from a different patient, the top electrocardiogram is from the atrial electrode, the middle electrocardiogram is from the ventricular pacing electrode, and the bottom electrocardiogram is from the defi brillation shock coil. In this patient, initial sinus rhythm degenerated into ventricular fi brillation. Following detection of ventricular fi brillation, a defi brillation shock was delivered (note that the defi brillation shock, as well as several seconds leading up to the shock, is not shown). The shock terminated the ventricular fi brillation, after which sinus beats were interspersed with paced beats and premature ventricular beats (not annotated). therapies for cardiac arrhythmias more volts.⁵⁹ Th e defi brillation discharge typically occurs along multiple vectors, such as one defi brillation coil to another, or one defi brillation coil to the pulse generator, depending upon the capabilities of the device and the options selected by the physician. Th is approach helps ensure adequate "coverage" of the fi brillating myocardium. Defi brillation originally used monophasic waveforms, in which one electrode polarity was used for the entire capacitive discharge. Newer devices typically use a biphasic waveform,⁶¹,⁶² in which the polarity of the waveform is reversed part way through the capacitive discharge, with factors such as timing of reversal and duty cycle varying between devices. Th e main advantage of the biphasic waveform is improved defi brillation effi cacy, specifi cally resulting in a reduction in the defi brillation threshold (the amount of energy required to defi brillate), often to <10 J. Reducing the defi brillation threshold provides a larger energy reserve in case initial defi brillation attempts fail, extends battery life, and reduces the possibility of tissue damage.
II.D. Ablation Therapy
As mentioned earlier, arrhythmias can arise from a focal region (resulting from triggered activity, abnormal automaticity, or microreentry), or can be due to a circus movement reentry (i.e., macroreentry), with the activation wave revolving around anatomical and/or functional obstacles. Regardless of the type, most tachyarrhythmias require one or more critical anatomical regions of abnormal excitability or propagation to be sustained. Recognizing this fact, catheter ablation of viable tissue in such a region was introduced as a therapy in the early 1980s, with the rationale that disruption of the required electrophysiological substrate would prevent recurrence of the arrhythmia.⁶³ Th e original approach of using high-voltage direct current shocks has since been replaced by radiofrequency catheter ablation, which can be more fi nely controlled and is less likely to cause damage to surrounding tissue. With this technique, radiofrequency energy destroys tissue in the reentrant circuit by resistive heating that creates a nonviable lesion. Radiofrequency ablation can be used for treatment of a number of arrhythmias, including supraventricular tachycardias, atrial fi brillation and fl utter, "idiopathic" ventricular arrhythmias, and reentrant ventricular tachycardias in patients with structural heart disease.
Perhaps the most diffi cult aspect of radiofrequency catheter ablation is localization of the correct ablation site. For localization of reentrant pathways for hemodynamically stable reentrant arrhythmias, a method known as "entrainment mapping" can be employed. In this approach, the target tachyarrhythmia is fi rst induced using the stimulation approaches discussed for the clinical electrophysiology study. Next, the pacing/ablation catheter is repeatedly repositioned within the suspected region of the heart. Trains of low-energy stimuli are then delivered at various sites while the arrhythmia continues, at a rate slightly faster (10-50 ms) than the intrinsic rate of the tachyarrhythmia. If the following criteria are met, the catheter location is thought to be in a "critical isthmus" for the reentrant rhythm and is therefore a good site for ablation: (1) there is an identical activation sequence of the heart chambers of interest (i.e., atria or ventricles) during pacing and during the tachyarrhythmia; (2) the time interval between each pacing stimulus and a fi xed reference point (either the QRS or P wave) in the electrocardiogram is identical to that between the electrocardiogram activation time at the catheter site and the activation time at the reference point during the tachyarrhythmia; and (3) the time between the delivery of the last stimulus and the point at which the catheter next senses electrical activity is identical (or within 30 ms).
Pace mapping is another localization method that can be used for either focal or reentrant arrhythmias. For pace mapping, trains of low-energy stimuli are also delivered from multiple catheter positions within the suspected target region. Th e location in which the observed surface electrocardiogram is morphologically identical to that of the targeted tachyarrhythmia is considered to be at, or in very close proximity to, the site of initiation of the arrhythmia. A more recent and sophisticated approach for localization of the arrhythmia uses electroanatomical mapping. Th is approach is analogous to the Global Positioning System, in that a catheter with a localization sensor on its tip is repeatedly repositioned within the heart. Electrophysiological recordings from each site are recorded and associated with a specifi c spatial location relative to a system of localization sensors located under the patient.
Once a suitable ablation site has been located, radiofrequency energy is delivered to produce a lesion. Especially for macroreentrant tachyarrhythmias, it is often necessary to reposition the catheter multiple times near the site to achieve an adequate scar, because radiofrequency lesions are relatively small in diameter and depth. For some persistent arrhythmias, it is immediately apparent when the ablation has been successful, because the arrhythmia terminates. For most tachyarrhythmias, however, successful ablation is quantifi ed according to the results of a follow-up clinical electrophysiology study. Even then, it is possible (although not typical) that an ablation lesion may be only transiently eff ective and that the arrhythmia might recur at a later date. However, unlike pharmacological therapy, successful ablation typically cures the patient of the arrhythmia.
III. FUTURE TREATMENT OF ARRHYTHMIAS
Two issues that we believe are crucial to improving the treatment of ventricular arrhythmias in the future are (1) improving the ability to predict the likelihood therapies for cardiac arrhythmias of having an arrhythmia based on clinically available measurements, and (2) understanding the chain of events that occurs immediately prior to (the trigger events) and during an arrhythmia so that intervention at the earliest point in time becomes possible. Whereas understanding the chain of events leading up to and during an arrhythmia will greatly benefi t implantable device technology and other intervention strategies, the ability to accurately determine a patient's vulnerability to particular arrhythmias will assist in deciding whether preventative treatment is required.
Future eff orts to improve the prediction of and probe the mechanisms underlying arrhythmias will likely be facilitated by the continued application of the physical principles of nonlinear dynamics to the study of cardiac dynamics.⁶⁴-⁶⁶ Among the more promising developments in cardiac electrophysiology within the past 20 years, nonlinear dynamic techniques have been able to shed much light on cardiac dynamics, predominantly because the electrophysiological behavior of the heart can be described mathematically using reaction-diff usion equations. Th ese equations have allowed cell-and tissue-level processes to be modeled at ever greater levels of detail,⁶⁷ allowing scientists to simulate the behavior of the heart under a wide variety of conditions that cannot easily be recreated during experiments. At the same time, nonlinear dynamics has also provided tools for the analysis of raw physiological data gathered from experiments, allowing many new insights into basic tissue dynamics to be obtained. As more and more scientists think about the heart as a nonlinear dynamic, the continued application of methods borrowed from physics and mathematics will likely contribute to a greater understanding of the electrophysiological dynamics of cardiac tissue and open up new avenues for arrhythmia therapies.
III.A. Noninvasive Arrhythmia Risk Assessment
Clinical electrophysiology studies are widely used for assessing the likelihood that a person will have a life-threatening arrhythmia. However, there are obvious benefi ts to being able to assess such risk noninvasively. To that end, numerous noninvasive tests are becoming available for identifying those patients who are at greatest risk for developing a ventricular tachyarrhythmia, many of whom would benefi t from implantation of an ICD. Electrocardiogram measurements that may help to assess susceptibility to arrhythmias include the occurrence of PVCs, QRS interval prolongation, QT interval dispersion, and ST segment elevation.⁶⁸ One potentially promising electrocardiogram measurement is T-wave alternans, a beat-to-beat fl uctuation in the amplitude or shape of the T wave.⁶⁹ T-wave alternans, a hypothetical (and exaggerated) example of which is illustrated in Fıgure 16, is important because it has been linked to a risk of occurrence of ventricular tachyarrhythmias, both experimentally⁷⁰-⁷³ and clinically.⁷⁴-⁸⁰ However, while fi ndings such as these demonstrate the potential signifi cance of noninvasive electrocardiogram markers for assessing potential risk for arrhythmias, unequivocal evidence to support the widespread use of any single measurement is lacking. It is likely, therefore, that a combination of risk evaluation techniques will have the greatest predictive power for identifying those patients who are most likely to benefi t from implantable devices.⁶⁸
III.B. Implantable Cardioverter Defi brillators
ICD technology continues to advance at a rapid rate. Many devices now off er both atrial and ventricular pacing capabilities in addition to their primary antitachycardia functions (as shown in Fıg. 15, after successful termination of the tachyarrhythmia). Advances in battery and capacitor technologies continue to enable smaller devices. Advances in therapeutic interventions continue to improve effi cacy and extend device longevity, while the ever-increasing quantity of diagnostic information stored in the device gives physicians extensive information for assessing the appropriateness of the device settings for any given patient.⁸¹ Although, unlike ablation, ICDs do not cure patients of their arrhythmic substrate, they are highly eff ective devices, with multiple studies demonstrating their signifi cantly superior mortality outcomes in appropriately selected, high-risk patients when compared to pharmacological interventions.⁵⁶ FIGURE 16 . Schematic representation of T-wave alternans. In this diagram, the electrocardiogram traces from two consecutive beats are overlaid, allowing the morphologies of the T waves to be directly compared. During T-wave alternans, the T wave morphology alternates on a beat-to-beat basis.
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Antitachycardia pacing is eff ective in terminating monomorphic (regular beat-to-beat morphology on an electrocardiogram trace) ventricular tachycardia in 80-90% of cases.⁸² Despite such a high rate of effi cacy, it may be possible to improve antitachycardia pacing by incorporating knowledge of the underlying nonlinear dynamics of reentry in future antitachycardia pacing algorithms.⁸³-⁸⁷ Fundamental issues relating to the delivery of defi brillation shocks at appropriate times also need to be resolved. Up to one-third of defi brillation shocks are given at inappropriate times,⁸⁸ even in dual-chamber devices.⁸⁹,⁹⁰ Th ese inappropriate shocks can cause intense pain and chronic anxiety. Improved detection algorithms may prevent unnecessary shocks from being delivered, but from the standpoint of survival, the results of a false-positive detection are likely to be far less detrimental than the results of a false-negative detection.⁹¹ Despite such shortcomings, ICDs will undoubtedly continue to save many lives in the years to come.
Defi brillation Therapy
Although ICDs are remarkably successful in terminating tachyarrhythmias, the reasons for the success of defi brillation remain controversial.⁹²,⁹³ Prominent theories for the mechanisms underlying defi brillation have included (1) the "critical mass" hypothesis, which states that reentrant waves in a critical mass of myocardium must be terminated so that the reentrant waves outside the critical mass occupy too small a volume of myocardium to sustain fi brillation, and thus self-extinguish; (2) the "extension of recovery" hypothesis, which states that defi brillation shocks act to prolong repolarization so that wavefronts occurring after defi brillation encounter refractory tissue and hence cannot propagate; and (3) the "synchronization of recovery" hypothesis, which states that defi brillation shocks synchronize repolarization so that wavefronts occurring after defi brillation do not encounter gradients of refractoriness (which, as was explained earlier, can lead to reentry and tachyarrhythmias).⁹⁴ Although there have been extensive experimental investigations of defi brillation and its mechanisms, the wide range of conditions and protocols used in these investigations has made validation of results and confi rmation or elimination of hypotheses diffi cult.⁹⁵ Th e advent of voltage-sensitive dye imaging (for experimentally mapping electrical activity⁹⁶) and the bidomain model (for simulating defi brillation on the computer⁹⁷) have allowed phenomena such as the post-shock isoelectric window and virtual electrode polarization to be studied and their relationship to defi brillation and shock-induced reentry to be explored.⁹⁸-¹⁰⁹ Recent work on defi brillation has been conducted in the context of phase resetting of oscillators¹¹⁰ and is based on the hypothesis that fi brillation consists of "wavelets," or short-lived sites of reentry, that wander around the myocardium.¹¹¹ In this context, each spiral wave is thought of as a limit cycle oscillator, and defi brillation can thus be thought of as the process of breaking the continuity of phase around each phase singularity (the core of each spiral wave) through phase resetting. Analyzing experimental defi brillation data using such methods from nonlinear dynamics⁹⁴,¹¹⁰ and using sophisticated mathematical models of the whole heart to simulate defi brillation on the computer¹⁰⁹,¹¹² may help to unify existing hypotheses about defi brillation mechanisms. However, numerous questions relating to the basic science of defi brillation still remain unanswered.⁹¹
Arrhythmia Onset Prediction
As a general rule, nonlinear dynamic systems (such as the electrophysiology of the heart) are more diffi cult to control when they are in a turbulent or disorganized state than when they are more ordered. Th is is why defi brillation requires high-energy shocks. Both in terms of device longevity and patient quality of life (defi brillation shocks are painful and distressing when delivered erroneously), it would be advantageous to "catch" the heart before it fi brillates. At present, antitachycardia pacing attempts to do this. However, both because antitachycardia pacing sometimes fails, and because fi brillation sometimes occurs directly from sinus rhythm (e.g., Panel B of Fıg. 15), it would be useful for an ICD to detect the imminent onset of an arrhythmia and prevent such onset, thereby preventing the heart from getting near its lethal, and diffi cult to control, disorganized states. An example of one promising arrhythmia predictor state is T-wave alternans. As previously mentioned, T-wave alternans is a long-term predictor of arrhythmia risk. It now appears that alternans may also be a short-term predictor of arrhythmia onset.¹¹³-¹¹⁵ Th e T wave is an indicator of apical-basal and/or transmural dispersion of repolarization in the ventricles.³⁷,³⁸,¹¹⁶ Th e prevailing hypothesis for the mechanism underlying T-wave alternans is that T-wave alternans is primarily caused by alternations in repolarization of the action potential (i.e., APD alternans).¹¹⁷ A recent study using guinea pig hearts demonstrated this by showing that the heart rate at which cellular APD alternans was initiated correlated with the heart rate at which T-wave alternans was observed in the electrocardiogram.⁴² Th e hypothesis that T-wave alternans may be a short-term predictor of arrhythmia onset is based on the fi ndings of numerous studies, both experimental⁴²,¹¹⁸-¹²¹ and computational,⁴⁰,⁴¹,¹²² that demonstrate that APD alternans can provide the substrate for triggering reentry.
Th e putative link between APD alternans and the initiation of ventricular tachyarrhythmias is as follows. As the heart rate is gradually increased, the APD therapies for cardiac arrhythmias pattern across the heart progressively changes from nonalternating, to concordant alternans, to discordant alternans. Th e subsequent introduction of a premature beat during discordant alternans may cause unidirectional block, as a result of the presence of steep gradients of repolarization. Th is unidirectional block may then lead to functional circus movement reentry and tachyarrhythmias.
Although there is strong evidence for a mechanistic link between T-wave alternans and the development of ventricular tachyarrhythmias, other arrhythmia predictor states may also exist. Th e analysis of data recovered from implanted devices in the time period immediately preceding an arrhythmia may be helpful in investigating these precursor events.¹²³ However, further research is required to determine whether the existence of such predictor states will lead to improved therapies.
Adaptive Control of Arrhythmias
Recent research has indicated that adaptive control algorithms, such as those originally developed for controlling nonlinear physical systems, may provide additional capabilities that potentially could lead to an improvement in the therapeutic efficacy of implantable devices such as ICDs.¹²⁴,¹²⁵ Th ese adaptive control algorithms may allow devices to terminate particular arrhythmias or their precursor events (as discussed in the previous section) using brief low-energy shocks. Such algorithms would provide an additional course of action for the device and may prevent the device from having to revert to higher energy (and potentially more painful) shocks to terminate the arrhythmia.
An example of a situation in which adaptive control algorithms may prove useful is in the termination of APD alternans to prevent the onset of a ventricular tachyarrhythmia. Given that cellular APD alternans has been demonstrated to be an important step in the development of reentry in vitro (as explained previously), it may be benefi cial to prevent APD alternans from occurring at all or to eliminate it as soon as possible after it has begun. Stabilizing the unstable period-1 solution (i.e., establishing action potentials of constant duration) underlying a stable period-2 solution (i.e., APD alternans) is one strategy for achieving this. Ideally, given the variation in cardiac tissue properties from person to person as well as within an individual person, an adaptive control algorithm would be able to stabilize the unstable period-1 solution without requiring extensive prior knowledge of the tissue dynamics, but rather would possess the ability to learn these dynamics "on the fl y."
Within the past few years, a number of control algorithms have been developed to establish a period-1 action potential rhythm in the presence of cellular APD alternans.¹²⁶-¹³³ Most of these algorithms stem from the Ott-Grebogi-Yorke (OGY) technique for controlling chaotic physical systems,¹³⁴ in which small perturbations are applied to an accessible system parameter in an attempt to force the state of the system toward the period-1 fi xed point. When applied to the heart, the most accessible system parameter available for perturbation is the timing of the next excitation, which can be advanced or (in some situations) delayed through low-magnitude current stimulation.
Th e utility of adaptive control algorithms for terminating potentially dangerous rhythms such as cellular APD alternans will only become obvious once further research is conducted into the eff ectiveness of such algorithms in controlling arrhythmias spatially as well as temporally. Initial computer simulations suggest that eliminating APD alternans at one site in a tissue will result in APD alternans being eliminated only up to a short distance away from the stimulation site.¹³¹,¹³³,¹³⁵ Recent experiments in canine Purkinje fi bers qualitatively confi rm these predictions.¹³⁶ However, the actual distance over which such control algorithms suppress alternans in ventricular tissue remains unknown. If multiple stimulation sites are necessary in order to simultaneously suppress APD alternans or other electrophysiological disturbances (i.e., either actual arrhythmias or their trigger events) in diff erent regions of the heart, a cardiac device that fi ts snugly around the ventricles, such as the Cor Cap™ Cardiac Support Device (Acorn Cardiovascular), which is now in clinical trials as a therapy for heart failure,¹³⁷,¹³⁸ could potentially be developed. Although many questions remain unanswered, the initial results of applying the principles of nonlinear dynamics and adaptive control to cardiac dynamics indicate the potential benefi t of continuing to think about arrhythmias in this way.
III.C. Ablation Therapy
Because of the shortcomings of radiofrequency ablation, much research has focused on the development of improved techniques and energy sources. One such promising advance is cryoablation, in which cryothermy is used to ablate cardiac tissue. An important advantage of this technique over radiofrequency ablation is the ability to reversibly test the eff ectiveness of an ablation site (by applying cryothermy for a brief period at a less extreme temperature, resulting in a reversible impairment of electrophysiological function) before proceeding to produce a permanent lesion (by application of cryothermy at colder temperatures for longer periods).¹³⁹ Additional experimental ablation modalities include ultrasound and microwave (which have better depth penetration than radiofrequency ablation) and diode lasers, which can deliver controlled low energy through a variety of fi ber confi gurations (such as loops) to achieve thin, continuous lesions in and around defi ned anatomical structures such as valve orifi ces.¹⁴⁰ therapies for cardiac arrhythmias
III.D. Pharmacological Treatment of Arrhythmias
Although the results of recent clinical trials have shifted the focus of treating arrhythmias away from pharmacological therapies and toward device and surgical interventions, there is still hope that new drug therapies may benefi t arrhythmia patients. However, given the increasing recognition of the diversity of mechanisms underlying arrhythmias, it will probably not be possible to design a single wonder drug to cure all arrhythmias. Instead, if such drugs are going to be useful for treating arrhythmias, their design will need to focus on the details of a particular arrhythmia, including its anatomical location in the heart, the ion channels implicated in its initiation and perpetuation, and the eff ect of the arrhythmia on tissue remodeling.
In general, antiarrhythmic drugs have thus far been designed to target mature ion channels, which represent the end product of a complex biochemical process of protein synthesis. Given that the occurrence of particular arrhythmias may be modulated by varying the amount of current carried by certain populations of ion channels, drugs that target ion channel proteins and their precursors during synthesis and assembly may be useful for increasing or decreasing the number of particular types of ion channels in the cell membrane.¹⁴¹ Th e recent appearance of atomic-resolution structures of ion channels¹⁴²,¹⁴³ will likely facilitate advances in antiarrhythmic drug design, as knowledge of the molecular composition of drug binding sites in ion channel proteins allows drugs to be tailored to interact with specifi c structural components of the channel, thus providing a means for increasing drug potency and specifi city.¹⁴¹ Another potentially promising line of research for arrhythmia drug design focuses on reducing the slope of the APD restitution curve. Recent research has indicated that ventricular fi brillation may develop when a single spiral wave (Fıg. 8) breaks up and forms multiple self-perpetuating wavelets.¹¹¹,¹⁴⁴ Evidence also exists that there is a close relationship between a steeply sloping APD restitution curve and the propensity to develop spiral wave breakup.¹⁴⁵-¹⁴⁷ Based on these observations, recent experiments have demonstrated that drugs that fl atten the APD restitution curve indeed prevent spiral wave breakup in pig heart preparations, and therefore such agents may hold great promise for preventing the development of ventricular fi brillation in humans.¹⁴⁸ However, such results must be tempered by the observation that tinkering with the electrophysiological substrate to cure one type of arrhythmia presents the risk of creating the ideal substrate for another.⁴⁶
III.E. Gene Therapy and Cell Therapy
In recent years, the transfer of genes into cardiac myocytes to alter their electrophysiological properties has been proposed as a strategy for treating arrhythmias. Although few in vivo studies have been conducted, in vitro studies indicate that gene therapy may have some utility for directly changing the morphology of the action potential in populations of cells within the heart. Before gene therapy becomes widespread, however, solutions to several technical problems, including the control of gene expression, the evaluation of potentially toxic eff ects, and the elimination of nontarget organ gene transfer and of host immune responses, will need to be found.¹⁴⁹ Th e transplantation of skeletal myoblasts and stem cells into regions of infarcted myocardium has been proposed as a way to improve myocardial function by replacing dead or diseased myocytes. In order for cell therapy to be widely clinically applicable, however, the optimal cell has to be compatible both mechanically and electrically with the host myocardium. At present, the optimal cell type and dose, delivery route, delivery catheter, and timing of cell injection remain unknown. In addition, although stem cell therapy has not been reported to induce cardiac arrhythmias in limited clinical trials to date, arrhythmias have been clinically associated with myoblast transplantation, and therefore investigators need to be watchful of arrhythmias in clinical trials of cell therapies.¹⁵⁰
IV. SUMMARY
Sudden cardiac death, primarily caused by ventricular tachyarrhythmias, is one of the leading causes of mortality in the United States. In recent decades, the understanding of what causes arrhythmias has improved dramatically through standard experimental and clinical methods, as well as through methods stemming from engineering and physics, including computational modeling and nonlinear dynamics. Accompanying this knowledge have been rapid and dramatic improvements in therapy, most notably implantable cardioverter defi brillators and radio-frequency ablation, which have saved thousands of lives and improved the standard of living for many more.
Such therapeutic advances notwithstanding, there remains room for signifi cant improvements in arrhythmia therapy, especially given that the number of people with heart disease, and the associated increased risk for arrhythmias, continues to increase. Th e possibilities for improvement are many: continued incremental improvements in ICDs (e.g., decrease in size; increase in battery life); introduction of new treatment modalities (such as cryoablation); and incorporation of new understandings of arrhythmia mechanisms (such as nonlinear-dynamic control methods and targeted drug design) are just a few. Because of the mathematical and technical nature of many aspects of arrhythmia and arrhythmia therapy research, it is likely that biomedical engineers will continue to make important contributions to this fi eld. It is our hope that this review will help to foster such involvement. 
